Table 1 Demographic and clinical features of POP patients
From: Female genital mutilation/cutting in sudan and subsequent pelvic floor dysfunction
No POP (Group 1) (n: 69) | Mild POP (Group 2) (n: 230) | Severe POP (Group 3) (n: 229) | Total (n: 528) | P value | ||
|---|---|---|---|---|---|---|
Age (median/min–max) | 42 (32–65) | 44 (31–88) | 49 [30–91] | 0.001a | ||
BMI (kg/m2) | < 25 | 25 (4,7%) | 74 (14%) | 29 (5.5%) | 128 (24.2%) | 0.001b |
≥ 25 | 44 (8.3%) | 156 (29.5%) | 200 (37.9%) | 400 (75.8%) | ||
Job | No | 43 (8.1%) | 135 (25.6%) | 93 (17.6%) | 271 (51.3%) | 0.001b |
Yes | 26 (4.9%) | 95 (18%) | 136 (25.8%) | 257 (48.7%) | ||
Parity | No | 7 (1.3%) | 15 (2.8%) | 6 (1.1%) | 28 (5.3%) | 0.027b |
Yes | 62 (11.7%) | 215 (40.7%) | 223 (42.2%) | 500 (94.7%) | ||
Urinary ıncontinence | No | 29 (5.5%) | 122 (23.1%) | 26 (4.9%) | 177 (33.5%) | 0.001b |
Yes | 40 (7.6%) | 108 (20.5%) | 203 (38.4%) | 351 (66.5%) | ||
HUN | No | 41 (7.8%) | 109 (20.6%) | 34 (6.4%) | 184 (34.8%) | 0.001b |
Yes | 28 (5.3%) | 121 (22.9%) | 195 (36.9%) | 344 (65.2%) | ||
Smoking | No | 68 (12.9%) | 214 (40.5%) | 205 (38.8%) | 487 (92.2%) | 0.041b |
Yes | 1 (0.2%) | 16 (3%) | 24 (4.5%) | 41 (7.8%) | ||
Assisted vaginal delivery | No | 45 (8.5%) | 163 (30.9%) | 62 (11.7%) | 270 (51.1%) | 0.001b |
Yes | 24 (4.5%) | 67 (12.7%) | 167 (31.6%) | 258 (48.9%) | ||
Delivery method | No | 7 (1.3%) | 15 (2.8%) | 6 (1.1%) | 28 (5.3%) | 0.001b |
VD | 52 (9.8%) | 170 (32.2%) | 201 (38.1%) | 423 (80.1%) | ||
C/S | 10 (1.9%) | 45 (8.5%) | 22 (4.2%) | 77 (14.6%) | ||
Parity | No | 7 (1.3%) | 15 (2.8%) | 6 (1.1%) | 28 (5.3%) | 0.001b |
1 | 22 (4.2%) | 65 (12.3%) | 30 (5.7%) | 117 (22.2%) | ||
02-May | 38 (7.2%) | 138 (26.1%) | 95 (18%) | 271 (51.3%) | ||
≥ 5 | 2 (0.4%) | 12 (2.3%) | 98 (18.6%) | 112 (21.2%) | ||
Residence | Rural | 43 (8.1%) | 153 (29%) | 165 (31.3%) | 361 (68.4%) | 0.227b |
Urban | 26 (4.9%) | 77 (14.6%) | 64 (12.1%) | 167 (31.6%) | ||
Educational status | No | 32 (6.1%) | 112 (21.2%) | 125 (23.7%) | 269 (50.9%) | 0.324b |
Read and write | 37 (7%) | 118 (22.3%) | 104 (19.7%) | 259 (49.1%) | ||
Menopausal status | No | 54 (10.2%) | 151 (28.6%) | 120 (22.7%) | 325 (61.6%) | 0.001b |
Yes | 15 (2.8%) | 79 (15%) | 109 (20.6%) | 203 (38.4%) | ||
Baseline comorbidity | No | 68 (12.9%) | 219 (41.5%) | 177 (33.5%) | 464 (87.9%) | 0.001b |
Yes | 1 (0.2%) | 11 (2.1%) | 52 (9.9%) | 64 (12.2%) | ||
FGM/C type | No | 7 (1.3%) | 16 (3%) | 9 (1.7%) | 32 (6.1%) | 0.001b |
Type 1 | 8 (1.5%) | 22 (4.1%) | 15 (6.6%) | 45 (8.5%) | ||
Type 2 | 34 (6.4%) | 96 (18.2%) | 55 (10.4%) | 185 (35%) | ||
Type 3 | 20 (3.8%) | 96 (18.2%) | 150 (28.4%) | 266 (50.4%) |